Karsdal Morten A, Madsen Suzi H, Christiansen Claus, Henriksen Kim, Fosang Amanda J, Sondergaard Bodil C
Nordic Bioscience A/S, Herlev Hovedgade 207, DK-2730 Herlev, Denmark.
Arthritis Res Ther. 2008;10(3):R63. doi: 10.1186/ar2434. Epub 2008 May 30.
Physiological and pathophysiological cartilage turnover may coexist in articular cartilage. The distinct enzymatic processes leading to irreversible cartilage damage, compared with those needed for continuous self-repair and regeneration, remain to be identified. We investigated the capacity of repair of chondrocytes by analyzing their ability to initiate an anabolic response subsequent to three different levels of catabolic stimulation.
Cartilage degradation was induced by oncostatin M and tumour necrosis factor in articular cartilage explants for 7, 11, or 17 days. The catabolic period was followed by 2 weeks of anabolic stimulation (insulin growth factor-I). Cartilage formation was assessed by collagen type II formation (PIINP). Cartilage degradation was measured by matrix metalloproteinase (MMP) mediated type II collagen degradation (CTX-II), and MMP and aggrecanase mediated aggrecan degradation by detecting the 342FFGVG and 374ARGSV neoepitopes. Proteoglycan turnover, content, and localization were assessed by Alcian blue.
Catabolic stimulation resulted in increased levels of cartilage degradation, with maximal levels of 374ARGSV (20-fold induction), CTX-II (150-fold induction), and 342FFGVG (30-fold induction) (P < 0.01). Highly distinct protease activities were found with aggrecanase-mediated aggrecan degradation at early stages, whereas MMP-mediated aggrecan and collagen degradation occurred during later stages. Anabolic treatment increased proteoglycan content at all time points (maximally, 250%; P < 0.001). By histology, we found a complete replenishment of glycosaminoglycan at early time points and pericellular localization at an intermediate time point. In contrast, only significantly increased collagen type II formation (200%; P < 0.01) was observed at early time points.
Cartilage degradation was completely reversible in the presence of high levels of aggrecanase-mediated aggrecan degradation. After induction of MMP-mediated aggrecan and collagen type II degradation, the chondrocytes had impaired repair capacity.
生理和病理生理状态下的软骨更新可能同时存在于关节软骨中。与持续自我修复和再生所需的酶促过程相比,导致不可逆软骨损伤的独特酶促过程仍有待确定。我们通过分析软骨细胞在三种不同程度的分解代谢刺激后启动合成代谢反应的能力,研究了软骨细胞的修复能力。
用抑瘤素M和肿瘤坏死因子诱导关节软骨外植体的软骨降解7、11或17天。分解代谢期后进行2周的合成代谢刺激(胰岛素生长因子-I)。通过II型胶原形成(PIINP)评估软骨形成。通过基质金属蛋白酶(MMP)介导的II型胶原降解(CTX-II)测量软骨降解,并通过检测342FFGVG和374ARGSV新表位来测量MMP和聚集蛋白聚糖酶介导的聚集蛋白聚糖降解。通过阿尔辛蓝评估蛋白聚糖的更新、含量和定位。
分解代谢刺激导致软骨降解水平升高,374ARGSV(诱导20倍)、CTX-II(诱导150倍)和342FFGVG(诱导30倍)达到最高水平(P < 0.01)。发现了高度不同的蛋白酶活性,早期是聚集蛋白聚糖酶介导的聚集蛋白聚糖降解,而后期是MMP介导的聚集蛋白聚糖和胶原降解。合成代谢治疗在所有时间点均增加了蛋白聚糖含量(最高可达250%;P < 0.001)。通过组织学检查,我们发现在早期时间点糖胺聚糖完全补充,在中间时间点细胞周围定位。相比之下,仅在早期时间点观察到II型胶原形成显著增加(200%;P < 0.01)。
在高水平的聚集蛋白聚糖酶介导的聚集蛋白聚糖降解存在的情况下,软骨降解是完全可逆的。在诱导MMP介导的聚集蛋白聚糖和II型胶原降解后,软骨细胞的修复能力受损。